FOOD AND DRUG ADMINISTRATION

Advertisements

Pharmaceutical Market Access Act (H.R. 2427): TREA Senior Citizens League, H9466 [15OC]

Amendments

Agriculture, rural development, FDA, and related agencies programs: making appropriations (H.R. 2673), S13927, S13943 [4NO], S13955, S13972, S13997, S13998, S14005, S14006, S14007, S14008, S14009, S14010, S14011, S14052, S14061, S14062, S14063, S14065, S14066, S14067, S14068, S14069 [5NO], S14104, S14106, S14118, S14128, S14131, S14140, S14142, S14143, S14145, S14182, S14183, S14184, S14185 [6NO], H6634, H6635, H6639, H6640, H6648, H6649, H6650, H6651, H6656, H6708 [14JY]

———making appropriations (H.R. 2673), consideration of conference report (H. Res. 473), H12765 [8DE]

———making appropriations (H.R. 2673), consideration of conference report—same-day consideration (H. Res. 458), H12185 [21NO]

———making appropriations (H.R. 2673), consideration of conference report—same-day consideration (H. Res. 465), H12758 [8DE]

Children and youth: provide authority to require certain research into drugs used in pediatric patients (S. 650), S9809, S9811, S9815 [23JY]

Federal Food, Drug, and Cosmetic Act: establish a program of fees relative to animal drugs (S. 313), S7165 [23MY], S7262 [3JN], S14279 [7NO]

Analyses

Oceans and Human Health Act (S. 1218), S7622 [10JN]

Appointments

Conferees: H.R. 2673, agriculture, rural development, FDA, and related agencies programs appropriations, S14155 [6NO], S14971 [17NO], H11379 [18NO]

Articles and editorials

Drug Maker Pushed Painkiller Aggressively; Purdue PHARMA Has Marketed OxyContin Far Beyond Its Original Purpose, Newly Released Documents Show, E1246 [13JN]

Health on the Border—Elderly Americans Head North and South To Find Drugs They Can Afford, H5347 [12JN]

Open Door to Drug Imports, H10540 [6NO]

Bills and resolutions

Abortion: withdraw approved application for the drug known as RU-486 and review process by which the FDA approved such drug (see S. 1930), S15407 [21NO] (see H.R. 3453), H10977 [6NO]

Agriculture: prohibit products containing dry ultra-filtered milk or casein from being labeled domestic natural cheese (see S. 40), S36 [7JA]

Agriculture, rural development, FDA, and related agencies programs: making appropriations (see S. 1427), S9592 [17JY] (see H.R. 2673), H6463 [9JY]

———making appropriations (H.R. 2673), consideration of conference report (see H. Res. 473), H12917 [8DE]

———making appropriations (H.R. 2673), consideration of conference report—same-day consideration (see H. Res. 458), H11700 [20NO] (see H. Res. 465), H12306 [21NO]

Children and youth: provide authority to require certain research into drugs used in pediatric patients (see S. 650), S3881 [18MR] (see H.R. 2857), H7615 [24JY]

Dept. of HHS: establish Offices of Women's Health (see S. 1304), S8300 [20JN]

———promulgate regulations for the reimportation of prescription drugs (see S. 1781), S13134 [23OC] (see H.R. 2427), H5266 [11JN]

———promulgate regulations for the reimportation of prescription drugs (H.R. 2427), consideration (see H. Res. 335), H7453 [23JY]

———take action to remove dietary supplements containing ephedrine alkaloids from the market (see S. Res. 260), S14177 [6NO] (see H. Res. 435), H10978 [6NO]

Dietary supplements: require manufacturers of dietary supplements submit reports on adverse experiences with dietary supplements (see S. 722), S4434 [26MR]

Diseases: improve data collection and dissemination between Federal and State registries to enhance the treatment and research of cancer (see S. 1899), S15287 [20NO]

Drugs: correct impediments to allowing importation of prescription drugs into the U.S. by pharmacists and wholesalers for resale and by U.S. citizens for personal use (see H.R. 780), H700 [13FE]

———enhance competition for prescription drugs by increasing enforcement of existing antitrust laws relative to brand name and generic drugs (see S. 946), S5484 [29AP]

———establish voluntary certification program for Internet and mail-order pharmacies and authorize, subject to conditions, importation of prescription drugs from Canada for personal use (see H.R. 2717), H6706 [14JY]

Federal Food, Drug, and Cosmetic Act: amend relative to dietary supplements (see H.R. 3377), H9981 [28OC]

———amend relative to dietary supplements containing ephedrine alkaloids (see H.R. 1075), H1515 [4MR]

———amend relative to new animal drugs (see S. 741), S4512 [27MR] (see H.R. 2079), H4011 [13MY]

———establish a program of fees relative to animal drugs (see S. 313), S1977 [5FE] (see H.R. 1260), H1900 [13MR]

———establish labeling and advertising requirements for dietary supplements containing ephedrine alkaloids and prohibit sales of such supplements to minors (see H.R. 725), H460 [12FE]

———establish recall authority for drugs and increase criminal penalties for sale or trade of prescription drugs knowingly adulterated or misbranded (see H.R. 3297), H9477 [15OC]

———establish requirements to allow sale of prescription drugs over the Internet (see H.R. 2652), H6263 [26JN]

———prohibit sale or trade of prescription drugs that were knowingly adulterated or misbranded (see H.R. 2936), H7783 [25JY]

———provide greater access to affordable pharmaceuticals (see S. 7), S34 (see S. 54), S36 [7JA] (see S. 1225), S7619 [10JN] (see H.R. 2491), H5467 [17JN] (see H.R. 2640), H6262 [26JN]

———require manufacturers of dietary supplements to register and require submission of reports on adverse experiences regarding such supplements (see H.R. 724), H460 [12FE]

———technical corrections relative to amendments made by the Medical Device User Fee and Modernization Act (see S. 1881), S15061 [18NO] (see H.R. 3493), H11358 [17NO]

Food: require certain ready-to-eat meat or poultry products to bear a label advising at-risk consumers of Dept. of Agriculture and FDA recommendations relative to listeria monocytogenes (see S. 1187), S7381 [4JN]

Health: improve access to prescription drugs, prohibit tax deductions for direct-to-consumer prescription drug advertisements, and ban campaign contributions from pharmaceutical company chief executive officers (see H.R. 1733), H3301 [10AP]

———permit an individual to be treated by a health care practitioner with any method of medical treatment such individual requests (see S. 1410), S9414 [15JY] (see H.R. 2085), H4129 [14MY]

———require notification by manufacturers before discontinuing production of a vaccine and develop a national vaccine stockpile (see S. 371), S2340 [12FE]

Health care professionals: establish restrictions relative to the qualifications of physicians prescribing the abortion drug known as RU-486 (see H.R. 486), H243 [29JA]

National Organization for Rare Disorders: anniversary (see H. Con. Res. 147), H3304 [10AP]

Oceans: establish an interagency research program to improve understanding of the role of the oceans and human health and a similar program at NOAA (see S. 1218), S7618 [10JN]

Orphan Drug Act: anniversary (see H. Con. Res. 147), H3304 [10AP]

Pharmaceuticals: eligibility of certain applicants for approval of a generic drug for a competition-free period (see H.R. 828), H702 [13FE]

———establish therapeutic equivalence requirements for generic drugs (see H.R. 3401), H10129 [29OC]

———impact of illegal importation of prescription drugs on regulatory protections afforded consumers (see H. Con. Res. 225), H5663 [19JN]

———permit commercial importation of prescription drugs from Canada (see H.R. 847), H703 [13FE] (see H.R. 2497), H5467 [17JN] (see H.R. 2769), H7085 [17JY]

———permit importation of prescription drugs from Canada and Mexico (see H.R. 2629), H6262 [26JN]

———provide access and choice for use of generic drugs under Federal health care programs (see S. 51), S36 [7JA]

Research: conduct oversight of any entity engaged in the recovery, testing, or handling of human tissue or human tissue-based products (see S. 1063), S6255 [14MY]

Safety: establish a comprehensive program to ensure food safety (see H.R. 1496), H2471 [27MR]

———uniform food safety warning notification requirements (see H.R. 2699), H6602 [10JY]

Taxation: treatment of direct-to-consumer advertisements of prescription drugs (see H.R. 149), H57 [7JA]

———treatment of direct-to-consumer advertisements of prescription drugs that fail to provide certain information to the consumer (see H.R. 3155), H8490 [23SE]

Tobacco products: eliminate quotas and price supports, compensate quota holders and producers, establish Tobacco Quality Board, assess user fees, and grant FDA authority to regulate tobacco (see H.R. 140), H56 [7JA]

Cloture motions

Agriculture, rural development, FDA, and related agencies programs: making appropriations (H.R. 2673), conference report, S16083 [9DE]

Conference reports

Agriculture, Rural Development, FDA, and Related Agencies Programs Appropriations (H.R. 2673), H12323-H12746 [25NO]

Descriptions

Marinol (Dronabinol) Capsules, H7308 [22JY]

Factsheets

Animal Drug User Fee Act Performance Goals and Procedures: FDA Center for Veterinary Medicine, S14791 [12NO]

Letters

Animal Drug User Fee Act: Tommy G. Thompson, Sec. of HHS, S14791 [12NO]

Collect and assess scientific evidence regarding prescription drugs frequently used by Medicare or Medicaid beneficiaries: Gail E. Shearer, Consumers Union (organization), S8420 [24JN]

———Ronald F. Pollack, Families USA (organization), S8421 [24JN]

———RxHealthValue (organization), S8420 [24JN]

Dept. of HHS certification of safety and cost savings relative to commercial importation of prescription drugs from Canada: Asa Hutchinson, DEA, S8206 [19JN]

———Donna E. Shalala, S8204 [19JN]

———Mark B. McClellan, FDA, S8203, S8205 [19JN]

———Tommy G. Thompson, Sec. of HHS, S8204 [19JN]

Enhance competition for prescription drugs by increasing enforcement of existing antitrust laws relative to brand name and generic drugs: Timothy J. Muris, FTC, S15886 [25NO]

FDA review of marketing and classification of the painkiller OxyContin for treatment of moderate pain: Representative Wolf, E2435, E2436 [23NO]

———Representative Wolf, Committee on Appropriations (House), E1245 [13JN], E2434 [23NO]

FDA withdrawal of approved application for the drug known as RU-486 and review approval process: Monty and Helen Patterson, S15474 [21NO]

Greater access to affordable pharmaceuticals: Business for Affordable Medicine (organization), H6121 [26JN]

Human Cloning Prohibition Act, H1407 [27FE]

———Kathryn C. Zoon, FDA, H1407 [27FE]

Include educational information about prescription drugs in direct-to-consumer advertising: several health organizations, S8609 [26JN]

Permit commercial importation of prescription drugs from Canada: Thomas Huebner and M. Betrice Grause, Vermont Association of Hospitals and Health Systems, E2174 [30OC]

Religious organizations' campaign opposing drug reimportation reform legislation due to increased accessibility to abortion drug known as RU-486: Representatives Pitts and Chris Smith, H6997 [16JY]

———Tom Coburn, H6593 [10JY], H6997 [16JY]

Safety of vaccines containing mercury and thimerosal: Representative Burton, E1981 [7OC]

Vaccines containing thimerosal: Mark B. McClellan, FDA, H8259 [16SE]

Lists

Counterfeit prescription drugs, H7597 [24JY]

Votes on point of order against Greater Access to Affordable Pharmaceuticals Act (2002), S15702 [24NO]

Motions

Agriculture, rural development, FDA, and related agencies programs: making appropriations (H.R. 2673), S14005 [5NO], S14142 [6NO], H6634 [14JY], H11372 [18NO]

Dept. of HHS: promulgate regulations for the reimportation of prescription drugs (H.R. 2427), H7610 [24JY]

Proposals

Treatment of biological products and generic drugs relative to patent challenges and exclusivity rules, S16106 [9DE]

Remarks in House

Abortion: remove the abortion drug known as RU-486 from market and review approval process, H10459 [6NO]

Agriculture, rural development, FDA, and related agencies programs: across-the-board funding reduction, H6648, H6649 [14JY]

———making appropriations (H.R. 2673), H6609-H6658, H6676-H6680 [14JY], H11372 [18NO], E1489 [15JY], E1504 [17JY], E1524, E1528, E1536 [18JY]

———making appropriations (H.R. 2673), conference report, H12315 [25NO], H12749, H12753, H12766-H12845, H12854, H12882, H12884 [8DE], E2460 [25NO], E2505, E2548, E2549 [8DE], E2551, E2556 [15DE]

———making appropriations (H.R. 2673), consideration of conference report (H. Res. 473), H12760-H12766 [8DE]

———making appropriations (H.R. 2673), consideration of conference report—same-day consideration (H. Res. 458), H12181-H12186 [21NO]

———making appropriations (H.R. 2673), consideration of conference report—same-day consideration (H. Res. 465), H12754-H12760 [8DE]

———making appropriations (H.R. 2673), motion to instruct conferees, H11372-H11377 [18NO], E2350 [20NO]

———making appropriations (H.R. 2673), unanimous-consent request, H6633 [14JY]

Children and youth: provide authority to require certain research into drugs used in pediatric patients (S. 650), H11567-H11572 [19NO]

Dept. of HHS: promulgate regulations for the reimportation of prescription drugs, H9354 [8OC], H9969 [28OC], H10539 [6NO], H11372-H11377, H11504, H11509-H11512 [18NO], H12106, H12111, H12178 [21NO], E2350 [20NO]

———promulgate regulations for the reimportation of prescription drugs (H.R. 2427), H5247 [11JN], H5453-H5459 [17JN], H6583, H6592-H6595 [10JY], H6682-H6685 [14JY], H6858-H6864 [15JY], H6873, H6996 [16JY], H7198, H7200, H7202 [21JY], H7457, H7458, H7459, H7595-H7611 [24JY], H7813 [3SE], H8261 [16SE], H9465 [15OC], E1617, E1621, E1622, E1642, E1647, E1648, E1658, E1659 [25JY]

———promulgate regulations for the reimportation of prescription drugs (H.R. 2427), consideration (H. Res. 335), H7531-H7541 [24JY]

———promulgate regulations for the reimportation of prescription drugs (H.R. 2427), motion to recommit, H7610 [24JY]

———take action to remove dietary supplements containing ephedrine alkaloids from the market (H. Res. 435), E2259 [6NO]

Drugs: correct impediments to allowing importation of prescription drugs into the U.S. by pharmacists and wholesalers for resale and by U.S. citizens for personal use, H8002 [5SE]

———discrepancy in prescription drug prices between U.S. and foreign countries, H4095 [14MY], H4342-H4349 [20MY], H4845 [3JN], H4953 [4JN], H5056-H5058 [9JN], H5155-H5159 [10JN], H5346, H5360-H5362 [12JN], H5453-H5459 [17JN], H6434 [9JY], H6858-H6864 [15JY], H9257 [7OC]

———review marketing of the painkiller OxyContin and its classification for treatment of moderate pain, E1245 [13JN], E2434 [23NO]

Federal Food, Drug, and Cosmetic Act: amend relative to dietary supplements (H.R. 3377), E2150 [28OC], E2192 [31OC]

———amend relative to new animal drugs (H.R. 2079), E940 [13MY]

———establish a program of fees relative to animal drugs (H.R. 1260), H9054-H9059 [1OC], E462 [13MR]

———establish a program of fees relative to animal drugs (S. 313), H10293-H10297 [4NO]

———establish labeling and advertising requirements for dietary supplements containing ephedrine alkaloids and prohibit sales of such supplements to minors (H.R. 725), E218 [13FE]

———establish requirements to allow sale of prescription drugs over the Internet (H.R. 2652), E1617 [25JY]

———require manufacturers of dietary supplements to register and require submission of reports on adverse experiences regarding such supplements (H.R. 724), E218 [13FE]

Government regulations: proposed rule for dietary supplement current good manufacturing practices, H7937 [4SE]

Health: safety of vaccines containing mercury and thimerosal, H9075 [1OC], E1981 [7OC]

———study link between child vaccinations and autism, H8258 [16SE], H9075 [1OC]

Metered dose inhalers: phaseout of those containing chlorofluorocarbons, H7666 [25JY]

National Organization for Rare Disorders: anniversary (H. Con. Res. 147), H4215-H4217 [19MY], E1000 [21MY]

Orphan Drug Act: anniversary (H. Con. Res. 147), H4215 [19MY], E1000 [21MY]

Pharmaceutical Market Access Act: lobbying activities, H7459 [24JY]

Pharmaceuticals: improve safety and efficacy for children, H11570 [19NO]

———permit commercial importation of prescription drugs from Canada, H6620, H6700 [14JY], E1489 [15JY], E2174 [30OC]

———permit commercial importation of prescription drugs from Canada (H.R. 847), H4768 [2JN]

———permit importation of prescription drugs, H9709 [20OC]

———provide greater access to affordable pharmaceuticals, H2313 [26MR]

———require manufacturers to sell FDA-approved prescription drugs to U.S. wholesalers and retailers on the same terms as Canadian purchasers, H12752 [8DE]

———safety of imported prescription drugs, H5249 [11JN], H9253, H9254 [7OC], H9800 [21OC], H11599 [19NO]

Public buildings: campus construction funding, H7857 [4SE]

Taxation: treatment of direct-to-consumer advertisements of prescription drugs that fail to provide certain information to the consumer (H.R. 3155), E1862 [23SE]

Remarks in Senate

Abortion: withdraw approved application for the drug known as RU-486 and review process by which the FDA approved such drug (S. 1930), S15473 [21NO]

Agency for Healthcare Research and Quality: collect and assess scientific evidence regarding prescription drugs frequently used by Medicare or Medicaid beneficiaries, S8419-S8421, S8422 [24JN], S8529, S8530 [25JN]

Agriculture: prohibit products containing dry ultra-filtered milk or casein from being labeled domestic natural cheese (S. 40), S45 [7JA]

Agriculture, rural development, FDA, and related agencies programs: making appropriations (H.R. 2673), S13900 [4NO], S13954, S13960-S13980, S13997-S14022 [5NO], S14104-S14107, S14110-S14155 [6NO], S14265 [7NO]

———making appropriations (H.R. 2673), conference report, S15917-S15920, S15933-S15935 [25NO], S16083-S16089, S16108 [9DE]

———making appropriations (H.R. 2673), conference report—unanimous-consent request, S16082 [9DE]

———making appropriations (H.R. 2673), insert S. 1427 language in lieu, S13954 [5NO]

———making appropriations (H.R. 2673), unanimous-consent agreement, S13891 [4NO], S14122 [6NO]

———making appropriations (H.R. 2673), unanimous-consent request, S13977 [5NO]

Appropriations: reduce for unrequested, low-priority, unnecessary, and wasteful spending programs, S14153 [6NO]

Center for Biologics Evaluation and Review: funding, S14265 [7NO]

Children and youth: provide authority to require certain research into drugs used in pediatric patients (S. 650), S3897 [18MR], S9811-S9819 [23JY]

Dept. of HHS: certify safety and cost savings relative to commercial importation of prescription drugs from Canada, S8203-S8215 [19JN], S8266-S8268 [20JN]

———drug addiction treatment programs funding, S4371 [25MR]

———establish Offices of Women's Health (S. 1304), S8302 [20JN]

———include educational information about prescription drugs in direct-to-consumer advertising, S8609 [26JN]

———promulgate regulations for the reimportation of prescription drugs, S15531 [22NO]

———promulgate regulations for the reimportation of prescription drugs (S. 1781), S13142, S13184 [23OC], S13187, S13207, S13229 [24OC]

———require drug companies to test drugs against their competitors, disclose results of such tests in advertising, and include educational information about the drug in direct-to-consumer advertising, S8484, S8485 [25JN]

Dietary Supplement Health and Education Act: enforcement funding, S14011 [5NO], S14151 [6NO], S15960 [25NO]

Dietary supplements: review safety of dietary supplements containing ephedrine, S14002 [5NO]

Diseases: improve data collection and dissemination between Federal and State registries to enhance the treatment and research of cancer (S. 1899), S15289 [20NO]

Drugs: discrepancy in prescription drug prices between U.S. and foreign countries, S2793 [26FE]

———enhance competition for prescription drugs by increasing enforcement of existing antitrust laws relative to brand name and generic drugs, S8012 [18JN], S8351 [23JN], S8429, S8431 [24JN], S15884-S15886 [25NO]

———enhance competition for prescription drugs by increasing enforcement of existing antitrust laws relative to brand name and generic drugs (S. 946), S5493, S5494 [29AP]

Federal Food, Drug, and Cosmetic Act: amend relative to new animal drugs (S. 741), S4530 [27MR]

———establish a program of fees relative to animal drugs (S. 313), S7165 [23MY], S7266 [3JN], S14279-S14282 [7NO], S14791 [12NO]

———provide greater access to affordable pharmaceuticals, S1506 [28JA], S8187-S8198, S8200 [19JN], S8689-S8692 [26JN]

———provide greater access to affordable pharmaceuticals (S. 54), S58 [7JA], S7966 [17JN]

———provide greater access to affordable pharmaceuticals (S. 7), S134-S136 [9JA]

———technical corrections relative to amendments made by the Medical Device User Fee and Modernization Act (S. 1881), S16057-S16060 [25NO]

Food: prohibit funding for process approving the human consumption of meat from downed animals, S13997 [5NO], S14150 [6NO]

Government regulations: prohibit sales of products such as dietary supplements containing ephedra or ephedrine alkaloids, S2511-S2513 [14FE], S2674-S2676 [25FE]

Health: permit an individual to be treated by a health care practitioner with any method of medical treatment such individual requests (S. 1410), S9422 [15JY]

———require notification by manufacturers before discontinuing production of a vaccine and develop a national vaccine stockpile (S. 371), S2356-S2358 [12FE]

Medicare: coverage of FDA-approved prescription drug therapies for beneficiaries with multiple sclerosis, S8546 [25JN]

Oceans: establish an interagency research program to improve understanding of the role of the oceans and human health and a similar program at NOAA (S. 1218), S7621 [10JN]

Pharmaceuticals: permit commercial importation of prescription drugs from Canada, S8186, S8203-S8215 [19JN], S8265, S8269 [20JN]

———require manufacturers to sell FDA-approved prescription drugs to U.S. wholesalers and retailers on the same terms as Canadian purchasers, S8332-S8335, S8341-S8343 [23JN], S8403 [24JN]

———treatment of biological products and generic drugs relative to patent challenges and exclusivity rules, S16104-S16107 [9DE]

Reports filed

Agriculture, Rural Development, FDA, and Related Agencies Programs Appropriations: Committee of Conference (H.R. 2673) (H. Rept. 108-401), H12320 [25NO]

———Committee on Appropriations (House) (H.R. 2673) (H. Rept. 108-193), H6463 [9JY]

———Committee on Appropriations (Senate) (S. 1427) (S. Rept. 108-107), S9591 [17JY]

Animal Drug User Fee Act: Committee on Energy and Commerce (House) (H.R. 1260) (H. Rept. 108-287), H9032 [30SE]

———Committee on Health, Education, Labor, and Pensions (Senate) (S. 313) (S. Rept. 108-51), S6851 [21MY]

Consideration of Conference Report on H.R. 2673, Agriculture, Rural Development, FDA, and Related Agencies Programs Appropriations: Committee on Rules (House) (H. Res. 473) (H. Rept. 108-402), H12917 [8DE]

Consideration of H.R. 2427, Pharmaceutical Market Access Act: Committee on Rules (House) (H. Res. 335) (H. Rept. 108-231), H7453 [23JY]

Oceans and Human Health Act: Committee on Commerce, Science, and Transportation (Senate) (S. 1218) (S. Rept. 108-203), S15186 [19NO]

Pediatric Research Equity Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 650) (S. Rept. 108-84), S8722 [26JN]

Same-Day Consideration of Consideration of Conference Report on H.R. 2673, Agriculture, Rural Development, FDA, and Related Agencies Programs Appropriations: Committee on Rules (House) (H. Res. 458) (H. Rept. 108-389), H11700 [20NO]

———Committee on Rules (House) (H. Res. 465) (H. Rept. 108-399), H12306 [21NO]

Summaries

Continuing Appropriations (H.J. Res. 2), S341-S345 [15JA]

Tables

Agriculture, rural development, FDA, and related agencies programs appropriations (H.R. 2673), H6610-H6617 [14JY]

———conference report, H12768-H12812, H12816-H12822 [8DE]

Committee on the Budget (Senate) scoring of conference report on H.R. 2673, agriculture, rural development, FDA, and related agencies programs appropriations, S16108 [9DE]

Committee on the Budget (Senate) scoring of H.R. 2673, agriculture, rural development, FDA, and related agencies programs appropriations, S13956 [5NO]

Vaccines containing thimerosal, H8259 [16SE]

Testimonies

Agriculture, Rural Development, FDA, and Related Agencies Programs Appropriations: Wenonah Hauter, Public Citizen (organization), H6621 [14JY]

Texts of

H. Con. Res. 147, anniversary of Orphan Drug Act and National Organization for Rare Disorders, H4215 [19MY]

H. Res. 335, consideration of H.R. 2427, Pharmaceutical Market Access Act, H7531 [24JY]

H. Res. 458, same-day consideration of conference report on H.R. 2673, agriculture, rural development, FDA, and related agencies programs appropriations and H.J. Res. 79, continuing appropriations, H12181 [21NO]

H. Res. 465, same-day consideration of consideration of conference report on H.R. 2673, agriculture, rural development, FDA, and related agencies programs appropriations and consideration of H.J. Res. 79, continuing appropriations, H12754 [8DE]

H. Res. 473, consideration of conference report on H.R. 2673, agriculture, rural development, FDA, and related agencies programs appropriations, H12760 [8DE]

H.R. 1260, Animal Drug User Fee Act, H9054-H9057 [1OC]

H.R. 2427, Pharmaceutical Market Access Act, H7595 [24JY]

H.R. 2673, agriculture, rural development, FDA, and related agencies programs appropriations, S14366-S14378 [10NO], H6625-H6633 [14JY]

S. 54, Greater Access to Affordable Pharmaceuticals Act, S55-S58 [7JA]

S. 313, Animal Drug User Fee Act, S7168-S7171 [23MY], S14279-S14282 [7NO], H10293-H10296 [4NO]

S. 371, require notification by manufacturers before discontinuing production of a vaccine and develop a national vaccine stockpile, S2357 [12FE]

S. 650, Pediatric Research Equity Act, S3898-S3900 [18MR], S9811-S9813, S9816-S9818 [23JY], H11567-H11569 [19NO]

S. 1187, At-Risk Consumer Protection Through Food Safety Labeling Act, S7401 [4JN]

S. 1218, Oceans and Human Health Act, S7623-S7625 [10JN]

S. 1881, Medical Devices Technical Corrections Act, S16058-S16060 [25NO]

S. Res. 260, Dept. of HHS action to remove dietary supplements containing ephedrine alkaloids from the market, S14180 [6NO]